Sanofi India Limited has announced that the Hon’ble Supreme Court of India, in its order dated 7th September 2026, dismissed the company’s petition seeking to quash ongoing criminal proceedings. The ruling pertains to the maintainability of criminal prosecution against the company, even in the absence of individual employee arraignment. The Supreme Court has not made any findings of guilt or adjudicated on the merits of the case. The criminal complaint remains pending for trial.
Supreme Court Ruling on Criminal Proceedings
Sanofi India Limited has informed stakeholders that the Hon’ble Supreme Court of India has dismissed its petition challenging criminal proceedings. The order, dated 7th September 2026, addresses the core issue of whether criminal prosecution can be maintained against the company when no individual employee is specifically named or arraigned. The Court’s decision clarifies that such proceedings can be valid. Importantly, the Supreme Court has made no finding of guilt against the company and has not adjudicated on the actual merits of the case.
Background of the Case
This matter stems from an appeal filed by Sanofi India Limited aimed at quashing a criminal complaint initiated by the Central Bureau of Investigation (CBI). The complaint relates to pharmaceutical supplies made to the Bhabha Atomic Research Centre (BARC) in Mysore between the years 2012 and 2015. The allegations involve a supposed conspiracy with a BARC personnel to wrongfully influence procurement decisions. As of the date of this disclosure, the criminal complaint case is still pending for trial.
Impact and Next Steps
The company is currently assessing the full implications of the judgment and is in the process of formulating its strategy for the next stage of litigation. At present, the judgment does not impose any penalty, conviction, or operational restriction on Sanofi India Limited. The company continues to evaluate the potential impact on its financial operations and other activities.
Source: BSE
